3D-QSAR study on 2,3-dihydroimidazo[4,5]-pyridin-2-one derivatives with a meta substitution pattern as V600EBRAF inhibitors

[1]  Zaheer Ul-Haq,et al.  A combined 3D-QSAR and molecular docking strategy to understand the binding mechanism of V600EB-RAF inhibitors , 2012, Molecular Diversity.

[2]  Wen-Hua Chen,et al.  Pyrrolo[3,2-d]pyrimidine Derivatives as Type II Kinase Insert Domain Receptor (KDR) Inhibitors: CoMFA and CoMSIA Studies , 2012, International journal of molecular sciences.

[3]  C. Springer,et al.  Small molecule inhibitors of BRAF in clinical trials. , 2012, Bioorganic & medicinal chemistry letters.

[4]  Shuguang Wu,et al.  Molecular docking and 3D-QSAR study on 4-(1H-indazol-4-yl) phenylamino and aminopyrazolopyridine urea derivatives as kinase insert domain receptor (KDR) inhibitors , 2012, Journal of Molecular Modeling.

[5]  P. Lan,et al.  3D-QSAR and molecular docking studies of azaindole derivatives as Aurora B kinase inhibitors , 2011, Journal of molecular modeling.

[6]  Chuan Yi Tang,et al.  Development of Novel 3D-QSAR Combination Approach for Screening and Optimizing B-Raf Inhibitors in silico , 2011, J. Chem. Inf. Model..

[7]  Jin Qin,et al.  Molecular Dynamics Simulation, Free Energy Calculation and Structure-Based 3D-QSAR Studies of B-RAF Kinase Inhibitors , 2011, J. Chem. Inf. Model..

[8]  Yong Ai,et al.  3D-QSAR and docking studies on pyridopyrazinones as BRAF inhibitors , 2011, Medicinal Chemistry Research.

[9]  G. Bottegoni,et al.  Non-ATP competitive protein kinase inhibitors. , 2010, Current medicinal chemistry.

[10]  D. Heimbrook,et al.  RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. , 2010, Cancer research.

[11]  Yuanqiang Wang,et al.  Docking and 3D QSAR study of thiourea analogs as potent inhibitors of influenza virus neuraminidase , 2010, Journal of molecular modeling.

[12]  Gen-Yan Liu,et al.  CoMFA and molecular docking studies of benzoxazoles and benzothiazoles as CYP450 1A1 inhibitors. , 2010, European journal of medicinal chemistry.

[13]  H. Mei,et al.  Docking and 3D-QSAR studies of influenza neuraminidase inhibitors using three-dimensional holographic vector of atomic interaction field analysis. , 2010, European journal of medicinal chemistry.

[14]  H. Dijkstra,et al.  BRAF inhibitors based on an imidazo[4,5]pyridin-2-one scaffold and a meta substituted middle ring. , 2010, Journal of medicinal chemistry.

[15]  M. Gordon,et al.  RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models , 2010 .

[16]  J. Settleman,et al.  Targeting the RAF-MEK-ERK pathway in cancer therapy. , 2009, Cancer letters.

[17]  Richard D. Taylor,et al.  Novel potent BRAF inhibitors: toward 1 nM compounds through optimization of the central phenyl ring. , 2009, Journal of medicinal chemistry.

[18]  C. McInnes,et al.  Non-ATP competitive protein kinase inhibitors as anti-tumor therapeutics. , 2009, Biochemical pharmacology.

[19]  Richard D. Taylor,et al.  Pyridoimidazolones as novel potent inhibitors of v-Raf murine sarcoma viral oncogene homologue B1 (BRAF). , 2009, Journal of medicinal chemistry.

[20]  K. Wong,et al.  Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway. , 2009, Recent patents on anti-cancer drug discovery.

[21]  Abran Q. Costales,et al.  Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors. , 2008, Journal of medicinal chemistry.

[22]  D. Fairlie,et al.  A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. , 2007, Drug discovery today.

[23]  C. Der,et al.  Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer , 2007, Oncogene.

[24]  Ajay N. Jain.  Surflex-Dock 2.1: Robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search , 2007, J. Comput. Aided Mol. Des..

[25]  Hieu T. Do,et al.  Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. , 2006, Cancer research.

[26]  M. Warmuth,et al.  A general strategy for creating , 2006 .

[27]  Taebo Sim,et al.  A general strategy for creating "inactive-conformation" abl inhibitors. , 2006, Chemistry & biology.

[28]  N. Gray,et al.  Rational design of inhibitors that bind to inactive kinase conformations , 2006, Nature chemical biology.

[29]  K. Balakin,et al.  Recent progress in development of non-ATP competitive small-molecule inhibitors of protein kinases. , 2006, Mini-Reviews in Medical Chemistry.

[30]  Mathew J Garnett,et al.  Guilty as charged: B-RAF is a human oncogene. , 2004, Cancer cell.

[31]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[32]  C. Pritchard,et al.  Raf proteins and cancer: B-Raf is identified as a mutational target. , 2003, Biochimica et biophysica acta.

[33]  Ajay N. Jain.  Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. , 2003, Journal of medicinal chemistry.

[34]  H. Kubinyi.  Comparative Molecular Field Analysis (CoMFA) , 2002 .

[35]  G. Klebe,et al.  Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. , 1994, Journal of medicinal chemistry.

[36]  R. Cramer,et al.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.